Scilex, a Sorrento Company, Announces Pivotal Phase 3

SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular...

Related Keywords

California ,United States ,New York ,San Diego ,Palo Alto ,Jaisim Shah ,Jeffrey Chi ,Deyo Weinstein ,Decisions Resources Group ,Semnur Pharmaceuticals Inc ,Practice Research Clinical Rheumatology ,Drug Administration ,Vickers Vantage Corp ,Nasdaq ,Scilex Holding Company ,Sorrento Therapeutics Inc ,Sorrento Company ,Pivotal Trialc Le Ar Program ,Scilex Pharmaceuticals Inc ,Company Or Scilex ,Holding Company ,Sorrento Therapeutics ,Lumbar Epidural Analgesia ,Text View ,Combined Company ,Securities Act ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Media Contact ,Nicolette Ten ,Senior Account Executive ,Semnur Pharmaceuticals ,Scilex Holding ,All Rights ,Research Clinical ,Chronic Pain ,Disease Landscape ,Nasdaq Srne ,Nc ,